CVS Health Corp. Stock

CVS Health’s FY2025 results present a striking contrast between robust top-line expansion and severely compressed profitability. Revenue crossed the $402 billion mark, yet net income attributable to shareholders shrank to roughly $1.77 billion from $4.61 billion the prior year—a decline of more than 60%. The reported net margin of just 0.44% and an operating margin of 1.16% highlight a year in which substantial one-time charges overshadowed the underlying business dynamics. Despite this, the share price rebounded from $44.25 at end-2024 to $80 by December 2025, which could suggest that investors looked through the non-cash impairment to focus on cash generation and the potential for earnings recovery.

Revenue growth of nearly 8% appears to have been driven primarily by higher premiums and product sales, while gross margin held fairly steady around 45%—a modest improvement over FY2024. The critical drag on operating profit was a $5.7 billion goodwill impairment in the Health Services segment, which single-handedly pushed reported operating income down to $4.66 billion. Absent that charge, operating earnings could have been roughly in line with or above the prior year’s $8.5 billion, though the trend of declining operating margins in earlier years—from 3.84% in FY2023 to 2.28% in FY2024—suggests that margin pressure was already present. The net impact is a business where top-line growth is being absorbed by rising costs or structural headwinds, with the impairment acting as a forceful acknowledgment of lower expectations for that segment.

From a balance-sheet standpoint, CVS Health appears conservatively capitalized. Total debt is offset by a healthy cash and short-term investment position, resulting in negative net debt and a debt-to-equity ratio of essentially zero. This net cash position provides a considerable buffer. However, working capital management paints a different picture: the current ratio of 0.84 and quick ratio of 0.63 are relatively low for a healthcare enterprise, potentially reflecting the significant insurance payables and pharmacy claims processing flows that tie up liquidity. The goodwill balance itself fell from $91.3 billion to $85.5 billion, primarily due to the Health Services writedown, but intangible-heavy assets still dominate the balance sheet.